Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01786447 · ClinicalTrials.gov registry record
Biomarkers of Brain Injury: Magnitude and Outcome of Mild and Moderate TBI
A clinical trial, sponsored by Banyan Biomarkers.
- Terminated
- Registry status
- 111
- Enrollment target
NCT01786447: Clinical Trial study, sponsored by Banyan Biomarkers.
NCT01786447 is a clinical trial that was terminated before completion, run by Banyan Biomarkers. The registered enrollment target is 111 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01786447 was terminated before completion, sponsored by Banyan Biomarkers.
- TERMINATED
- Registry status
- 111 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if specific brain injury biomarkers have utility as blood-based traumatic brain injury (TBI) diagnostic and monitoring tools. This will be accomplished by examining the relationships between potential serum-based TBI biomarkers and clinical measures of injury severity, occurrence of complications, and outcome, in subjects with mild or moderate TBI as well as in orthopedic control subjects.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-03 |
Why NCT01786447 stopped before completion
NCT01786447 is an observational study that tracks outcomes without assigning an intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01786447 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01786447 about?
NCT01786447 is a clinical study titled "Biomarkers of Brain Injury: Magnitude and Outcome of Mild and Moderate TBI". The purpose of this study is to determine if specific brain injury biomarkers have utility as blood-based traumatic brain injury (TBI) diagnostic and monitoring tools. This will be accomplished by examining the relationships between potential serum-based TBI biomarkers and clinical measures of injur...
What is the current status of trial NCT01786447?
This trial is currently terminated. The enrollment target is 111 participants. The study started on 2010-04. Estimated completion is 2011-03.
Who is sponsoring clinical trial NCT01786447?
This trial is sponsored by Banyan Biomarkers, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia